Bromhidrosis Disease Treatment

Bromhidrosis Disease Treatment

Global Bromhidrosis Disease Treatment Market to Reach US$1.2 Billion by 2030

The global market for Bromhidrosis Disease Treatment estimated at US$756.3 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2023-2030. Apocrine Body Odor Treatment, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$742.8 Million by the end of the analysis period. Growth in the Eccrine Body Odor Treatment segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$206.0 Million While China is Forecast to Grow at 11.1% CAGR

The Bromhidrosis Disease Treatment market in the U.S. is estimated at US$206.0 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$264.6 Million by the year 2030 trailing a CAGR of 11.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Bromhidrosis Disease Treatment Market - Key Drivers and Trends Summarized

 

Bromhidrosis, commonly known as body odor, is a medical condition characterized by excessive and offensive body odor caused by bacterial decomposition of sweat. This condition primarily affects the apocrine sweat glands found in areas such as the armpits and groin. Bromhidrosis can be classified into two types: apocrine and eccrine. Apocrine bromhidrosis is associated with the bacterial breakdown of sweat, while eccrine bromhidrosis is linked to the decomposition of sweat from the eccrine glands on the skin`s surface. Treatment for bromhidrosis aims to reduce sweat production, minimize bacterial activity, and manage the odor effectively.

The treatment landscape for bromhidrosis has evolved considerably, incorporating both medical and non-medical approaches. Traditional treatments include the use of topical antiperspirants and deodorants that contain aluminum chloride to reduce sweat and mask the odor. For more severe cases, physicians may prescribe antibiotics to address bacterial infections or recommend antiseptic washes to reduce bacterial load on the skin. Additionally, treatments such as botulinum toxin (Botox) injections have gained popularity for their ability to temporarily block nerve signals responsible for sweating. Surgical options, including the removal of sweat glands and sympathectomy, offer more permanent solutions for severe cases. Recent advancements also include laser treatments and microwave thermolysis, which target and destroy overactive sweat glands, providing long-term relief from symptoms.

The growth in the bromhidrosis treatment market is driven by several factors. Firstly, the increasing awareness and social stigma associated with body odor have led more individuals to seek medical treatment, boosting demand for effective therapies. Secondly, advancements in dermatological research and technology have expanded treatment options, making them more accessible and efficient. Additionally, the rise in disposable incomes and improved healthcare infrastructure, particularly in developing regions, has facilitated greater access to both non-invasive and surgical treatments. The growth of e-commerce and telemedicine platforms has also made it easier for patients to access specialized treatments and consultations. Furthermore, the aging population, which is more prone to sweat-related issues, has increased the need for advanced bromhidrosis treatments. Lastly, strategic marketing efforts by pharmaceutical and cosmetic companies to promote awareness and the benefits of their products have played a crucial role in driving market expansion.

Select Competitors (Total 86 Featured) -

• Avanor Healthcare Ltd
• Cantabria Labs
• Clutch, Inc. (DBA Carpe)
• Ducray Dermatological Laboratories
• Galderma SA
• Ipsen Pharma
• Medytox, Inc.
• Merz Pharma
• No More Sweat
• Pampered Skin Care, LLC
• Salve Pharmaceuticals Pvt. Ltd.
• Seaford Pharmaceuticals Inc.
• The Polar Company B.V.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.